Johnson & Johnson's Traumatic Purchase

About a month ago, the rumors started up that Johnson & Johnson (NYSE: JNJ  ) was looking to make a significant purchase of $10 billion or more. And earlier this week we got our answer: Swiss medical device maker Synthes has agreed to be purchased for about $21.6 billion. Let's dig in and see what this means for Johnson & Johnson investors.

Synthes already controls half of the $5 billion trauma market and pulls in almost $1 billion in annual sales from its spine division while competing with Zimmer (NYSE: ZMH  ) and Alphatec (Nasdaq: ATEC  ) . Post-merger, Johnson & Johnson's DePuy division will be the leader in trauma, hips, and extremities, and second in spine and knees. And it won't just be in a slight lead; its nearest competitor, Stryker (NYSE: SYK  ) , will pull in only about half of DePuy's projected revenue.

One sticking point is the structure of the deal. It was originally assumed by most analysts that Johnson & Johnson would be using its cash from outside the U.S. to fund the majority of the purchase. By turning that low-interest cash into a productive acquisition, some thought that this deal would be accretive to the tune of about 5% of 2014's earnings, but J&J was forced to go a different route.

It turns out that Synthes is not the Swiss company it is made out to be! Although it doesn't trade on U.S. exchanges and is founded by a Swiss billionaire, Synthes in fact has a headquarters in the not-at-all foreign locale of West Chester, Penn. As a result, Johnson & Johnson will issue stock to pay for 65% of the deal, adding roughly an additional 8% to the share count in the process. Worse yet, this will turn what was initially assumed to be a really positive deal into one that is slightly dilutive for the next couple of years.

And then there is the Federal Trade Commission. Whether this deal can stand is also up for debate. Johnson & Johnson is projecting confidence, but my money is thinking the health-care giant won't come out unscathed. Likely victims are J&J's own trauma unit or a spine unit from one of the two companies.

It's an outside possibility, but if the FTC puts the kibosh on the whole thing, that leaves Johnson & Johnson likely looking for a relatively smaller and more acceptable target. Several names that were bandied around before news of the Synthes deal leaked including high-tech equipment maker Intuitive Surgical (Nasdaq: ISRG  ) , which would pair up well with Johnson & Johnson's Ethicon division; and low tech hospital suppliers CR Bard (NYSE: CRB  ) or CareFusion (NYSE: CFN  ) , both of which have key synergies while providing increased access to emerging markets. An international diagnostics player, like France's bioMerieux, could also make a lot of sense.

Assuming it's basically smooth sailing for this deal, where does it leave investors? On one hand, Johnson & Johnson looks to have paid a fair price for a company that is a natural fit, even if it has to divest the spine business, but J&J missed out on the opportunity to put its large stockpile of foreign cash to work. That's frustrating. With the share dilution, it may be some time before existing shareholders see any marked gains from this deal. I'm not super excited, but over the long term, it looks like the juice was probably worth the squeeze.

David Williamson owns shares of Johnson & Johnson. Johnson & Johnson and Stryker are Motley Fool Inside Value recommendations. Intuitive Surgical is a Motley Fool Rule Breakers recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is also a Motley Fool Income Investor selection. The Fool owns shares of Johnson & Johnson and Zimmer Holdings. Alpha Newsletter Account, LLC owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (12)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1485526, ~/Articles/ArticleHandler.aspx, 10/2/2014 9:08:08 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement